The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 9 | — | 20.8x | Bottom tier | |
Growth | 50 | 39.0% | 6.1% | Around median | |
Quality | 37 | -54.2% | 6.6% | Bottom tier | |
Safety | 76 | 1.1x | 0.7x | Top tier | |
Capital Return | 67 | — | 2.02% | Top tier | |
Momentum | 95 | 402.9% | 4.1% | Top tier | |
Sentiment | 42 | 10 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Tango Therapeutics, Inc. (TNGX) is a leading biotechnology company focused on discovering and developing targeted therapies for cancer patients using synthetic lethality technologies. The company's business model relies on developing a pipeline of innovative therapies and generating revenue through collaboration agreements and strategic partnerships for drug development and clinical trials, with a focus on solid tumors that are difficult to treat with traditional methods.
On the financial front, the trailing twelve months (TTM) results for 2026 showed the company achieved revenues of $57.0 million, while recording a net loss of $68.5 million, representing a loss per share of approximately $0.48. In the first quarter of 2026, the company recorded a net loss of $45.5 million, with an EPS of -$0.32. This follows a full fiscal year in 2025 in which the company generated revenue of $62.4 million against a net loss of $101.6 million (EPS of -$0.87), despite achieving temporary profitability in the third quarter of 2025 with a net income of $15.9 million and an EPS of $0.13.
Tango Therapeutics enjoys a strong analyst consensus recommending a Buy, with the average estimated price target for the stock at $42.7, with expectations ranging between a low of $24 and an optimistic high of up to $69. Given the historical 52-week trading range of $4.4 to $32.79, the stock is currently trading below the analyst consensus average target, indicating strong potential upside linked to the success of its future clinical trials.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
In the first quarter of 2026, Tango Therapeutics recorded a net loss of $45.5 million, representing a loss of $0.32 per share. As for the trailing twelve months (TTM) period of 2026, the company's revenue reached $57.0 million with a total net loss of $68.5 million. These figures reflect the ongoing high operating costs associated with research and development compared to the generated revenues.
The company ended fiscal year 2025 with total revenue of $62.4 million, but recorded an annual net loss of $101.6 million, resulting in a negative EPS of -$0.87. However, the third quarter of 2025 saw an exceptional performance where the company achieved positive net income of $15.9 million and an EPS of $0.13. This contrast demonstrates how milestone payments or partnerships can temporarily and positively impact the company's quarterly results.
The stock experienced a significant rise of 57% on June 8, 2026, following the announcement of promising clinical results for the treatment of advanced pancreatic cancer and an analyst upgrade of the stock's price target. This was followed by another jump of 51% on June 11, 2026, after the medical community described the pancreatic cancer treatment results as unprecedented. This positive clinical data significantly boosted investor confidence in the company's ability to develop successful and commercially viable therapies.
Automated analysis for informational purposes only — not investment advice.
Insider transactions at the company indicate a strong sell signal over the past three months, with the net value of sales reaching $1.2 million. Four insider sales transactions were recorded with absolutely zero purchases during this period. The last recorded insider transaction took place on June 1, 2026, which may raise some caution among retail investors regarding the internal valuation of the stock.
The average price target for Tango Therapeutics stock by analysts is $42.7, reflecting significant optimism about the company's clinical future. Analyst estimates range from a conservative low of $24 to a highly optimistic high of $69. This optimism aligns with the overall analyst consensus, which currently rates the stock as a Buy based on the recent clinical data for pancreatic cancer.